Data / Form D filings / Actinium Pharmaceuticals, Inc.
Actinium Pharmaceuticals, Inc.: Form D filings
Actinium Pharmaceuticals, Inc., a pharmaceuticals company in New York, NY, filed 6 Form D notices with the SEC between 2013 and 2014. The latest, on January 21, 2014, reports $6.6 million sold of a $6.6 million offering to 63 investors.
Find out what Actinium Pharmaceuticals, Inc. does, who founded it and who invested, beyond what the filing says. $10 of credit on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 501 FIFTH AVENUE, 3RD FLOOR, New York, NY, 10017
- Phone
- (646) 459-4201
- Industry
- Pharmaceuticals
- Entity type
- Corporation
- Incorporated in
- Delaware
- Revenue range
- No Revenues
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1388320
The full lists. Form D filings in New York: 4,357 rows, $123.57, or the new rows each week for $19 a month. Form D filings in Pharmaceuticals: 346 rows, $17.30, or the new rows each week for $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (company, CIK, year incorporated, street, city, state and 5 more), which open on your screen as soon as the payment clears and come by email. For agents and scripts: every list with its row count and price is at https://specstream.ai/data/lists.json.
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Jan 21, 2014 | Amendment | $6,636,720 | $6,636,720 | $0 | 63 | Dec 27, 2013 | sec.gov |
| Jan 7, 2014 | New notice | $6,000,000 | $3,325,860 | $2,674,140 | 36 | Dec 27, 2013 | sec.gov |
| Oct 8, 2013 | New notice | Indefinite | $0 | Indefinite | 25 | Sep 25, 2013 | sec.gov |
| Sep 4, 2013 | New notice | Indefinite | $0 | Indefinite | 13 | Aug 22, 2013 | sec.gov |
| Mar 19, 2013 | New notice | Indefinite | $0 | Indefinite | 348 | Mar 11, 2013 | sec.gov |
| Jan 14, 2013 | New notice | Indefinite | $0 | Indefinite | 60 | Dec 28, 2012 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Dragan J. Cicic | Executive Officer | |
| David J. Nicholson | Director | |
| Sergio J. Traversa | Executive Officer, Director | |
| Kaushik J. Dave | Executive Officer, Director | |
| Sandesh J. Seth | Director | |
| Richard I. Steinhart | Director |
Other pharmaceuticals companies in New York that filed recently
- NBO Pharma Inc. $238,000 · Nov 9, 2026
- Pierrepont Therapeutics, Inc. $2.4 million · Sep 22, 2026
Every Form D from the week of Jan 20, 2014 · All recent filings in New York · All recent Pharmaceuticals filings
Read from SEC EDGAR. Amount sold is what Actinium Pharmaceuticals, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.
$10 of credit on sign-up, no card.